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Background: Current vaccines protect against human papillomavirus (HPV) types 16 and 18, which are 
associated with approximately 70% of cervical cancer and 50% of high-grade cervical lesions. Monitoring 
trends in HPV 16/18-associated lesions is important to assess vaccine impact.  
Methods: Cervical intraepithelial neoplasia (CIN) grades 2 and 3 and adenocarcinoma in situ (AIS) cases 
of women residing in the catchment area of New Haven County, CT were reported to the Connecticut 
HPV-IMPACT surveillance system, and diagnostic specimens were obtained for HPV DNA testing. Cases 
were geocoded to census tracts and linked to area-based measures of race, ethnicity, and poverty. 
Statistical analysis included logistic regression modeling and generalized estimating equations. This 
analysis included 1,820 New Haven County women aged 21-39 years diagnosed with CIN2+ from 2008-
2014 who had at least one of the fifteen high-risk HPV types detected in the diagnostic specimen.  
Results: A total of 825 (45.3%) cases had HPV 16 or 18. Declines in prevalence of HPV 16/18 in lesions 
were observed, and in a model controlling for age and diagnosis grade, the year 2012 was associated 
with a lower likelihood of HPV 16/18 compared to the year 2008 (p=0.004). There was a significant 
interaction between year and area-based race with less of a decline in women living in areas with higher 
proportion of black residents (p=0.028). Among 21-24 year old women (n=552), there was a more 
evident decline in likelihood of HPV 16/18 in the lesions controlling for diagnosis grade, but the decline 
did not occur for women in areas of higher proportions of black, Hispanic, and poor residents. 
Conclusion: These results suggest that the proportion of lesions attributed to HPV 16/18 have declined 
in New Haven County, CT, particularly among young women, but the declines are not observed in areas 
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 Human papillomavirus (HPV) is the most common sexually transmitted infection in the United 
States [1]. The overall prevalence of infection has been estimated at 27% among US women aged 14-59 
years, with the highest prevalence of infection among females ages 20-24 [2]. Infection with HPV can 
cause genital warts as well as high-grade cervical lesions that are known precursors of invasive cervical 
carcinoma, and HPV infection is recognized as a necessary cause of cervical cancer [3, 4]. Despite 
declines in cervical cancer incidence and mortality due to screening, 12,000 women in the US were 
diagnosed with cervical cancer in 2012 [5]. HPV types found in cervical cells have been classified as low 
or high risk of progression to malignancy based on their epidemiological association with invasive 
cervical cancer [6]. HPV types 16 and 18 are associated with approximately 70% of cervical cancer 
worldwide [7]. In addition to types 16 and 18, types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82 
are considered high-risk types [6]. High-grade cervical lesions, including cervical intraepithelial neoplasia 
(CIN) grades 2 and 3 and adenocarcinoma in situ (AIS), are important outcomes in monitoring of HPV 
trends because they are considered precancerous and closely related to the development of cervical 
cancer, with CIN grade 3 and AIS being the most immediate precursors to invasive cervical cancer [8].   
 Three highly efficacious prophylactic HPV vaccines that protect against HPV types 16 and 18 
have been licensed by the US Food and Drug Administration since 2006 [9, 10]. All three are 
recommended for routine use among adolescents [9, 10]. The quadrivalent HPV vaccine has been 
predominantly used in the US since its licensure in 2006, which protects against the low-risk HPV types 6 
and 11 that are associated with genital warts, in addition to types 16 and 18 [9]. The newest vaccine was 
licensed in 2014 and is a 9-valent vaccine that protects against five additional high-risk types: 31, 33, 45, 
52, and 58 [10]. As it takes decades for cervical cancer to develop, monitoring of other HPV-associated 
clinical outcomes is important to demonstrate population-level impact of vaccination. Studies from 
worldwide data sources to demonstrate the impact of these HPV vaccines show promising results in 
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consistent and significant declines in HPV-related clinical outcomes among young women, including 
genital warts and HPV infection [11, 12]. From 2008 to 2012, prevalence of HPV types 16 and 18 in 
CIN2+ lesions statistically significantly decreased among women in the US who received at least one 
dose of the vaccine across of five catchment areas in California, Connecticut, New York, Oregon, and 
Tennessee [13].  
An important aspect in monitoring HPV vaccine impact is observing differences or disparities by 
race, ethnicity, and socioeconomic status. In Connecticut, disparities have been shown in rates of high-
grade cervical lesions, and women living in areas of higher levels of poverty and higher proportions of 
black residents had higher rates of CIN2+ lesions in the early vaccine era of 2008 and 2009 [14]. Black 
race, Hispanic ethnicity, and higher area-based poverty were all found to be associated with a lower 
likelihood of HPV 16 and 18 among women in Connecticut with high-grade cervical lesions in 2008 to 
2010, which suggests that HPV vaccines could potentially have a lower impact among black and Hispanic 
women and those living in high poverty areas [15]. It has also been shown that there is an interaction 
between individual race and ethnicity and area-based measures of race being associated with higher 
rates of high-grade cervical lesions in Connecticut in 2008 to 2011 [16].  
The goal of this analysis is to explore the trends in HPV 16/18-associated high-grade cervical 
lesions over time in New Haven County, Connecticut from 2008-2014, and to examine trends by 
individual and area-based measures of race, ethnicity, and poverty to observe potential disparities.    
 
Methods 
Design, Case Ascertainment, and Definitions 
Surveillance methods have been described previously [14, 17]. The Centers for Disease Control 
and Prevention (CDC) established the HPV-IMPACT surveillance system in 2008 in collaboration with the 
Emerging Infections Program (EIP) Network to monitor the impact of HPV vaccination through 
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population-based surveillance of high-grade cervical lesions [18]. At the Connecticut (CT) site, diagnoses 
of high-grade cervical lesions, specifically cervical intraepithelial neoplasia (CIN) grades 2 and 3 and 
adenocarcinoma in situ (AIS), were added to the list of statewide mandatory reportable diseases in 2008 
by the Connecticut Department of Public Health [19]. All 34 surgical pathology laboratories in the state 
are currently in compliance with this reporting requirement. Reports include diagnostic information as 
well as patient demographics. Standardized reports and samples of diagnostic histopathology specimens 
of CIN2+ and AIS cases of women aged 18-39 years residing in the catchment area of New Haven 
County, CT are sent to the CDC for HPV DNA testing [18]. Enhanced surveillance activities for cases 
residing in New Haven County include medical chart reviews and patient interviews to collect additional 
demographic and health history information. According to 2010 US Census data, New Haven County has 
a total population of 862,474, including 13% black and 15% Hispanic residents. The US Census 2006-
2010 American Community Survey estimates that 11% of the individuals in New Haven County live 
below the federal poverty level. There are 189 census tracts in New Haven County, CT.  
We analyzed data from cases reported during January 1, 2008 through December 31, 2014 in 
the catchment area of New Haven County, CT and for whom HPV typing results had been received from 
the CDC. Cases aged 21-39 and with at least one of the fifteen types of HPV that are considered high-risk 
detected in the diagnostic specimen were include in this analysis. Presence of HPV 16/18 was defined as 
detection of either type in a lesion, irrespective of presence of other types. Diagnoses are reported as 
CIN2, CIN3, CIN2/3 (grade not specified), AIS only, or AIS + CIN. In order to reflect the high-grade lesions 
that are more immediate precursors to invasive cervical cancer, and due to the small sample size of 
women diagnosed with AIS, cases were classified for this analysis into one of two diagnosis categories: 
CIN2 and CIN2/3, and CIN3 and AIS with or without CIN. Individual race and ethnicity measures obtained 
from surveillance reports were combined to form a single race/ethnicity variable with four categories: 
non-Hispanic white, Hispanic, non-Hispanic black, and other race or unknown. Insurance information 
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from reports was classified into broader categories of private, public insurance or no insurance, and 
other/missing. The cases were grouped into four categories based on age at the time the lesion was 
detected: 21-24, 25-29, 30-34, and 35-39 years. 
 
Geocoding and Geographic Measures 
Cases were geocoded to the census tract level using residential addresses, a method that has 
been previously described [14, 16]. Census tracts are small subdivisions of counties that are relatively 
homogenous in population characteristics, and therefore can be used as proxies for neighborhoods [20]. 
Using geocoded surveillance data and geographic sociodemographic measures from US census data has 
been shown to be appropriate to examine health disparities [20-22]. Cases were then linked to census 
tract-level measures of race, ethnicity, and poverty. Area measures of race and ethnicity were obtained 
from 2010 US Census data and included percentage of the female population that are black and 
Hispanic, respectively. The percentage of the female population living below the federal poverty level at 
the census tract level is obtained from the US Census 2006-2010 American Community Survey 5-year 
estimates. These area-based measures were examined in binary categories (≥20% and <20%), which are 
adapted from the cut-points used in the Public Health Disparities Geocoding Project, with the three 
lower levels collapsed into one category for analysis purposes [20].  
 
Statistical analyses 
 The primary outcome for analysis was presence of HPV 16/18 DNA detected in the diagnostic 
specimen. To first determine associations with the proportion of high-grade cervical lesions with HPV 
16/18, a Chi-square test was used for each variable. Binary logistic regression modeling was then 
conducted for each individual-level variable (year, age group, diagnosis, race/ethnicity, and insurance), 
using indicator variables in the model for any variables that had more than two categories, to determine 
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unadjusted associations with the prevalence of HPV 16/18. For the area-based measure variables, 
generalized estimating equations were used and the census tract variable was included in the model to 
account for the correlation between women residing in the same census tract.  
To examine the adjusted effect of year, the predictor of interest, on the proportion of HPV 
16/18-associated lesions, diagnosis grade and age group were included in the model to adjust for 
potential confounding. Diagnosis is controlled for because more immediate precursors of cervical cancer 
(CIN3 and AIS) are more likely to have HPV 16/18.  
A series of models were run to assess the interaction between year and the various individual 
and area-based measures. A model was run for each individual and area-based sociodemographic 
variable (race/ethnicity, insurance, area race, area ethnicity, and area poverty) to determine significance 
of the independent effects of the variable and the interaction between year and the variable of interest. 
All of these models included diagnosis and age to control for potential confounding.  
Chi-square tests were used to evaluate associations between year and presence of HPV 16/18 in 
lesions, stratified by age group. The modeling analyses were then repeated, restricting the sample to the 
21-24 year old age group. For purposes of this analysis, years were combined into three categories to 
mediate the effects of a smaller sample size: 2008-2009, 2010-2011, and 2012-2014.  As with the 
previous set of models, a series of models were run to test the significance of each variable and its 
interaction with year in this subset of the sample.  
All statistical analyses were conducted using SAS version 9.4. Significance was determined at the 
α=0.05 level unless otherwise indicated. 
 
Results 
From 2008 to 2014, a total of 2,106 New Haven County women aged 21 to 39 years were 
diagnosed with CIN2+, reported to the Connecticut HPV-IMPACT surveillance system, and had HPV 
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typing completed. Of these, 1,842 (87.5%) had at least one of the fifteen high-risk HPV types detected in 
the diagnostic specimen. We successfully geocoded 1,820 (98.8%) of cases.  
A total of 825 (45.3%) cases in the sample had either HPV type 16 or 18 detected in the lesion, 
including 743 (40.8%) women with HPV 16 only, 92 (5.1%) with HPV 18 only, and 10 (0.6%) with both 
HPV 16 and 18 detected  (Figure 1, Table 1). The other high-risk types most frequently detected in this 
sample were HPV type 31 (13.9%) and HPV 52 (11.1%), and 11.8% of cases have 2 of more HPV high-risk 
types detected in diagnostic specimens (Figure 1). Moderate declines were observed in the prevalence 
of HPV 16/18 in lesions over time during 2008-2014, with the most evident decline observed in the 21-
24 year old age group in the sample (Figure 2). 
In the unadjusted main effects analysis, black women were significantly less likely to have HPV 
16/18 compared to white women in the sample (prevalence ratio [PR]: 0.60, 95% confidence interval 
[CI]: 0.45, 0.80, Table 2). The main predictor of interest, year, indicates a decrease in the likelihood of 
HPV 16/18 in lesions for every year compared to 2008, though the only year that was significant was 
2012 (p=0.008, Table 2). When adjusting for the effects of age and diagnosis type, women in 2012 were 
61% as likely to have HPV 16/18 as women in 2008 (p=0.004, Table 3). In this adjusted analysis, the years 
2013 and 2014 are marginally significant at the α=0.10 significance level (adjusted PR=0.69, p=0.097 and 
adjusted PR=0.64, p=0.093 respectively).  
To determine the effects of individual and area-based measures on the prevalence of HPV 16/18 
over time, a series of multivariate models adjusting for potential confounding by age and diagnosis were 
conducted, with interaction terms to determine if there was an interaction between year and the 
specific measure of interest. There was a significant interaction between year and area-based race 
(p=0.028), controlling for age and diagnosis. Women in areas with ≥20% of black residents did not show 
a decline over time in the prevalence of HPV 16/18 compared to women living in areas with <20% of 
black residents (Figure 3). There was no significant interaction between year and individual 
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race/ethnicity, insurance status, area-based ethnicity, or area-based poverty (p=0.241, p=0.345, 
p=0.254, p=0.154, respectively). 
A post-hoc analysis of only the women in the sample aged 21-24 years old was completed. Age 
group was determined to be an effect modifier of the relationship between the main effect of interest, 
year, and the prevalence of HPV 16/18- associated lesions through stratification of the sample by age 
group. There is a significant association between year and prevalence of HPV 16/18 in the 21-24 year old 
age group (Chi-square, p=0.004), but not in the 25-29, 30-34, or 35-39 year age groups (Chi-square, 
p=0.303, p=0.599, p=0.615, respectively).  
For this post-hoc analysis we restricted analyses to the women ages 21-24 (n=522) where there 
was the most evident decline in the proportion of lesions attributed to HPV 16/18 (Figure 2). As a 
consequence of the smaller sample size, years were combined into 2008-2009, 2010-2011, and 2012-
2014 to examine the changes in the proportion of lesions attributable to HPV 16/18 over time. In an 
unadjusted analysis among women aged 21-24, cases living in areas with ≥20% of residents of Hispanic 
ethnicity were significantly more likely to have HPV 16/18-associated lesions (PR: 1.42, 95% CI: 1.01, 
2.00, Table 4). Adjusting for diagnosis type, women of age 21-24 with a high-grade lesion diagnosed in 
the years 2012-2014 were 61% less likely to have HPV 16/18 than women in 2008-2009 (95% CI: 0.40, 
0.63, p<0.001, Table 5).  
In a series of multivariate models for these 21-24 year old women adjusting for potential 
confounding by diagnosis, there were significant interactions between year and area-based race, 
ethnicity, and poverty (p=0.038, p=0.013, and p=0.005, respectively). Young women from areas with 
<20% of black residents, <20% Hispanic residents, and <20% residents living in poverty showed declines 
in the prevalence of HPV 16/18 by the years 2012-2014. Young women from areas with ≥20% of black 
residents did not show as significant a decline in the prevalence of HPV 16/18 compared to the women 
living in areas with <20% of black residents, and the women from areas with ≥20% of Hispanic residents 
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or ≥20% of residents living in poverty showed no decrease in prevalence of HPV 16/18 over time (Figure 
4). There was no significant interaction between year and individual race/ethnicity or insurance status 
among these women (p=0.578, p=0.790, respectively). 
 
Discussion 
 Analyzing the distribution of HPV types 16 and 18 in high-grade lesions is important to assess 
vaccine impact. In addition, analyzing this distribution by race, ethnicity, and sociodemographic factors 
is important for determining if the vaccine impact is different among specific populations. This analysis 
expands our current knowledge about disparities in HPV 16/18 prevalence by individual and area-based 
measures by examining the changes over time.  
In this analysis we observed declines in the proportion of lesions with a high-risk type of HPV 
that have HPV 16/18 from 2008-2014. This relationship over time significantly interacts with area race, 
and declines are less evident in women who live in areas with a higher proportion of black residents. 
Among young women in the sample aged 21-24, the decline in the prevalence of HPV 16/18 in these 
high-grade lesions differs by area race, area ethnicity, and area poverty. The decline is observed for 
women in areas of lower proportions of black, Hispanic, and poor residents, but not among the women 
in areas of higher minorities and a higher proportion of residents living below the poverty level. These 
findings are consistent with previous declines in high-grade cervical lesions observed in young women in 
Connecticut from 2008-2011, where significant declining trends occurred in census tracts with lower 
proportions of the population being black, Hispanic, or living in poverty [17]. Our analysis extends these 
previous trend analyses by examining the specific HPV vaccine types 16/18 and over a longer period of 
time.  
In these data, the overall trend of proportion of lesions with HPV 16/18 is a moderate decline 
over time, but upon further exploration of the effect of age on this trend, the overall decline is subdued 
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by the women of older ages in the sample. The decline in the proportion of lesions with HPV 16/18 is 
more evident in those women ages 21-24, which is to be expected as these women are more likely to be 
vaccinated and more likely to be impacted by vaccination. Increasing vaccination rates among young 
women is a possible explanation for the decline in prevalence of HPV 16/18 in lesions observed here. An 
important consideration in the interpretation of these findings however is that we can only assess 
indirect vaccine impact.  
This study has some limitations. Women could only be included in this analysis if the HPV DNA 
testing results had been completed at CDC. This resulted in a smaller number of samples in the later 
years of our trend analysis, as recent specimens were pending specimen processing at the CDC and 
typing results were not yet completed or received. While this presents a potential sample size issue, 
particularly in using a subset of the data for analysis, it is not likely that the typing results received or not 
yet received in the more recent years presented bias in the results. Another potential limitation is 
missing demographic information for some cases, particularly for individual-level race and ethnicity for 
which was missing in 28% of cases in the analysis. For many of the variables used in the analysis, 
categories had to be created and combined in order to prevent having levels of variables that were too 
small to be interpreted, such as more detailed individual race or ethnicity, insurance type, or diagnosis 
type categories. Without an ability to measure trends in the general population, we have used the 
proportion of high-grade lesions that detect HPV 16/18 to assess trends over time. Changes in cervical 
cancer screening guidelines that recommend less frequent screening is a possible explanation for 
declines in the rates of high-grade cervical lesions, but by examining the prevalence of these types 
among lesions that were reported we should be avoiding any bias as a result of this. 
A strength of this analysis is the use of population-based surveillance data with HPV-type 
specific results. Using high-grade lesions that are reportable to the state of Connecticut gives us 
confidence that we have high case ascertainment for women living in the catchment area of New Haven 
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County. The use of geocoded data allows us to assess disparities at the area-based level in addition to 
individual factors. These findings suggest that monitoring specific HPV types by both individual and area-
based measures of race, ethnicity, and poverty is important. Future research is needed to better 
understand these results and what is driving these disparities. Some possible explanations to explore 
include different patterns in vaccine uptake, such as timing of vaccination relative to initiation of sexual 
activity or initiation of vaccination compared to completion of the three-dose series. Differential 
distributions of HPV types among populations and differences in screening patterns are additional 
considerations in the interpretation of these findings and how these disparities can best be addressed in 
practice. Further, additional research can determine if these vaccine-types continue to persist in areas of 
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Figure 1. High-Risk Human Papillomavirus (HPV) Type Prevalence in CIN 2+ Cases Among Women Aged 
21-39 Years in New Haven County, Connecticut During 2008-2014 (n=1,820). Presence of types is not 



























Table 1. Characteristics of CIN2+ Cases with High-Risk HPV Types Among Women Aged 21-39 Years in 












































All data are presented as n (column %). Percentages may not sum to 100% due to rounding. 
Abbreviations: AIS, adenocarcinoma in situ; CIN, cervical intraepithelial neoplasia. 






Other High Risk 
(n=995) 
pa 
Year    0.150 
    2008 400 (22.0) 199 (24.1) 201 (20.2)  
    2009 304 (16.7) 136 (16.5) 168 (16.9)  
    2010 338 (18.6) 158 (19.2) 180 (18.1)  
    2011 367 (20.2) 169 (20.5) 198 (19.9)  
    2012 225 (12.4) 87 (10.6) 138 (13.9)  
    2013 110 (6.1) 47 (5.7) 63 (6.3)  
    2014 76 (4.2) 29 (3.5) 47 (4.7)  
Age Group    0.004 
    21-24 552 (30.3) 238 (28.9) 314 (31.6)  
    25-29 612 (33.6) 312 (37.8) 300 (30.2)  
    30-34 431 (23.7) 188 (22.8) 243 (24.4)  
    35-39 225 (12.4) 87 (10.6) 138 (13.9)  
Diagnosis Type    <0.001 
    CIN 2, 2/3 1313 (72.1) 516 (62.6) 797 (80.1)  
    CIN 3, AIS ± CIN 507 (27.9) 309 (37.5) 198 (19.9)  
Race/Ethnicity    0.001 
    White 942 (51.8) 463 (56.1) 479 (48.1)  
    Hispanic 326 (17.9) 148 (17.9) 178 (17.9)  
    Black 256 (14.1) 94 (11.4) 162 (16.3)  
    Other/Unknown 296 (16.3) 120 (14.6) 176 (17.7)  
Insurance    0.218 
    Private 1087 (59.7) 510 (61.8) 577 (58.0)  
    Public/None 596 (32.8) 259 (31.24 337 (33.9)  
    Other/Missing 137 (7.5) 56 (6.8) 81 (8.1)  
Area-based Measures     
Area race    0.076 
    <20% black 1297 (71.3) 605 (73.3) 692 (69.6)  
    ≥20% black 523 (28.7) 220 (26.7) 303 (30.5)  
Area ethnicity    0.631 
    <20% Hispanic 1247 (68.5) 570 (69.1) 677 (68.0)  
    ≥20% Hispanic 573 (31.5) 255 (30.9) 318 (32.0)  
Area poverty    0.702 
    <20% in poverty 1340 (73.6) 611 (74.1) 729 (73.3)  
    ≥20% poverty 480 (26.4) 214 (25.9) 266 (26.7)  
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Figure 2. Trends in Prevalence of HPV 16/18 in CIN2+ Cases with High-Risk HPV Types During 2008-
2014 in New Haven County, Connecticut, by Age Group 
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Table 2. Prevalence of HPV 16/18 in CIN2+ Cases with High-Risk HPV Types Among Women Aged 21-39 












































Abbreviations: AIS, adenocarcinoma in situ; CIN, cervical intraepithelial neoplasia. 
  
 Unadjusted Prevalence 
Ratio  (95% CI) 
p 
Year   
    2008 1.00  
    2009 0.82 (0.61, 1.10) 0.187 
    2010 0.89 (0.67, 1.18) 0.416 
    2011 0.86 (0.65, 1.15) 0.306 
    2012 0.64 (0.46, 0.89) 0.008 
    2013 0.75 (0.49, 1.15) 0.193 
    2014 0.62 (0.38, 1.03) 0.065 
Age Group   
    21-24 1.20 (0.88, 1.65) 0.254 
    25-29 1.65 (1.21, 2.25) 0.002 
    30-34 1.23 (0.88, 1.71) 0.223 
    35-39 1.00  
Diagnosis Type   
    CIN 2, 2/3 1.00  
    CIN 3, AIS ± CIN 2.41 (1.95, 2.97) <0.001 
Race/Ethnicity   
    White 1.00  
    Hispanic 0.86 (0.67, 1.11) 0.243 
    Black 0.60 (0.45, 0.80) <0.001 
    Other/Unknown 0.71 (0.54, 0.92) 0.010 
Insurance   
    Private 1.00  
    Public/None 0.87 (0.71, 1.06) 0.173 
    Other/Missing 0.78 (0.55, 1.12) 0.182 
Area-based Measures   
Area race   
    <20% black 1.00  
    ≥20% black 0.83 (0.67, 1.03) 0.085 
Area ethnicity   
    <20% Hispanic 1.00  
    ≥20% Hispanic 0.95 (0.78, 1.17) 0.641 
Area poverty   
    <20% in poverty 1.00  
    ≥20% poverty 0.96 (0.77, 1.20) 0.716 
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Table 3. Prevalence of HPV 16/18 in CIN2+ Cases with High-Risk HPV Types Among Women Aged 21-39 


















 Adjusted Prevalence 
Ratio  (95% CI) 
p 
Year   
    2008 1.00  
    2009 0.85 (0.62, 1.15) 0.285 
    2010 0.91 (0.68, 1.23) 0.548 
    2011 0.87 (0.65, 1.16) 0.346 
    2012 0.61 (0.43, 0.85) 0.004 
    2013 0.69 (0.44, 1.07) 0.097 
    2014 0.64 (0.39, 1.08) 0.093 
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Figure 3. Prevalence of HPV 16/18 in CIN2+ Cases with High-Risk HPV Types Among Women Aged 21-
39 Years During 2008-2014, by Area-Based Race  
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Table 4. Prevalence of HPV 16/18 in CIN2+ Cases with High-Risk HPV Types Among Women Aged 21-24 





































 Unadjusted Prevalence 
Ratio  (95% CI) 
p 
Year   
    2008-2009 1.00  
    2010-2011 0.92 (0.63, 1.35) 0.685 
    2012-2014 0.39 (0.24, 0.63) <0.001 
Diagnosis Type   
    CIN 2, 2/3 1.00  
    CIN 3, AIS ± CIN 2.64 (1.74, 4.02) <0.001 
Race/Ethnicity   
    White 1.00  
    Hispanic 0.98 (0.61, 1.56) 0.933 
    Black 0.71 (0.44, 1.16) 0.172 
    Other/Unknown 1.09 (0.67, 1.78) 0.724 
Insurance   
    Private 1.00  
    Public/None 1.19 (0.83, 1.72) 0.344 
    Other/Missing 0.93 (0.47, 1.81) 0.826 
Area-based Measures   
Area race   
    <20% black 1.00  
    ≥20% black 1.02 (0.71, 1.47) 0.895 
Area ethnicity   
    <20% Hispanic 1.00  
    ≥20% Hispanic 1.42 (1.01, 2.00) 0.045 
Area poverty   
    <20% in poverty 1.00  
    ≥20% poverty 1.40 (0.98, 2.01) 0.066 
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Table 5. Prevalence of HPV 16/18 in CIN2+ Cases with High-Risk HPV Types Among Women Aged 21-24 




Ratio  (95% CI) p 
Years   
2008-2009 1.00  
2010-2011 0.87 (0.59, 1.28) 0.468 
2012-2014 0.39 (0.40, 0.63) <0.001 
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Figure 4. Prevalence of HPV 16/18 in CIN2+ Cases with High-Risk HPV Types Among Women Aged 21-
24 Years During 2008-2014, by Area-Based Measures of Race (Panel A), Ethnicity (Panel B), and 
Poverty (Panel C) 
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